Diligence memo · auto-generated · as of July 2, 2026
Ganymede Bio, Inc.
Ganymede Bio, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ganymede Bio, Inc. operates in Biotech / Pharma, based in PALO ALTO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ganymede Bio, Inc. has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $15M on 2022-07-25.
Most recent recorded round closed around 2022-07-25.
Valuation (modeled)modeled
Provath models Ganymede Bio, Inc. at approximately $239M (range $31M–$619M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.91× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.9 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 69% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Carbon Biosciences, Inc., Slingshot Biosciences, Inc., Nueva Bio LLC, Telesis Bio Inc., Turn Biotechnologies, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.